Linked Life Data

19356647

Source:http://linkedlifedata.com/resource/pubmed/id/19356647

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2009-4-9
pubmed:abstractText
Non-muscle invasive bladder cancer is the most expensive cancer to manage on a per patient basis due to the high recurrence rate, low mortality and the need for long term, often lifelong surveillance. Current white-light endoscopic surgery leads to a significant number of patients having "recurrent" cancer at their first follow-up cystoscopy. The introduction of a single dose of intravesical chemotherapy immediately after the initial resection has helped to reduce the recurrence rate but it can be toxic and should not be administered to patients with potential bladder perforations after transurethral resection of bladder tumour (TURBT). Photodynamic diagnosis cystoscopy has been shown to significantly improve the quality of the initial TURBT leading to a 20% reduction in tumour recurrences at 3 months. This benefit is sustained for at least 8 years, leading to a reduction in further invasive procedures and treatment. Despite the initial increased cost related to introducing a photodynamic diagnosis service there is clearly long-term significant cost savings to be made, as well as improving the patient experience and quality of life.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1873-1597
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
153-8
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer.
pubmed:affiliation
Barnet and Chase Farm Hospitals NHS Trust, Wellhouse Lane, Barnet, London, Herts EN5 3DJ, United Kingdom.
pubmed:publicationType
Journal Article, Review